Helen McShane
#47,574
Most Influential Person Now
British virologist
Helen McShane's AcademicInfluence.com Rankings
Helen McShanebiology Degrees
Biology
#5564
World Rank
#8076
Historical Rank
Virology
#351
World Rank
#359
Historical Rank
Download Badge
Biology
Helen McShane's Degrees
- PhD Virology University of Oxford
Why Is Helen McShane Influential?
(Suggest an Edit or Addition)According to Wikipedia, Helen Irene McShane is a British infectious disease physician and a professor of vaccinology, in the Jenner Institute at the University of Oxford, where she has led the tuberculosis vaccine research group since 2001. She is senior research fellow at Harris Manchester College, Oxford.
Helen McShane's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial (2013) (897)
- Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans (2004) (622)
- Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. (2001) (482)
- Enhanced Immunogenicity and Protective Efficacy Against Mycobacterium tuberculosis of Bacille Calmette-Guérin Vaccine Using Mucosal Administration and Boosting with a Recombinant Modified Vaccinia Virus Ankara1 (2003) (405)
- Direct Ex Vivo Analysis of Antigen-Specific IFN-γ-Secreting CD4 T Cells in Mycobacterium tuberculosis-Infected Individuals: Associations with Clinical Disease State and Effect of Treatment1 (2001) (395)
- COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II (2020) (392)
- Multifunctional, High-Level Cytokine-Producing Th1 Cells in the Lung, but Not Spleen, Correlate with Protection against Mycobacterium tuberculosis Aerosol Challenge in Mice (2008) (301)
- Enhanced Immunogenicity of CD4+ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis (2001) (250)
- Immunisation with BCG and recombinant MVA85A induces long‐lasting, polyfunctional Mycobacterium tuberculosis‐specific CD4+ memory T lymphocyte populations (2007) (246)
- Viral Booster Vaccines Improve Mycobacterium bovis BCG-Induced Protection against Bovine Tuberculosis (2009) (239)
- Safety and efficacy of MVA 85 A , a new tuberculosis vaccine , in infants previously vaccinated with BCG : a randomised , placebo-controlled phase 2 b trial (2013) (236)
- A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. (2004) (236)
- T-cell activation is an immune correlate of risk in BCG vaccinated infants (2016) (225)
- MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques (2009) (215)
- Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study (2021) (201)
- Modified vaccinia Ankara‐expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells (2009) (193)
- Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. (2005) (173)
- Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. (2008) (172)
- Protective Immunity against Mycobacterium tuberculosis Induced by Dendritic Cells Pulsed with both CD8+- and CD4+-T-Cell Epitopes from Antigen 85A (2002) (144)
- The human immune response to tuberculosis and its treatment: a view from the blood (2015) (143)
- Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. (2005) (143)
- Tuberculosis vaccines: beyond bacille Calmette–Guérin (2011) (138)
- Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial (2014) (136)
- Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. (2006) (133)
- Establishment of an Aerosol Challenge Model of Tuberculosis in Rhesus Macaques and an Evaluation of Endpoints for Vaccine Testing (2010) (129)
- Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. (2009) (125)
- Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. (2006) (120)
- Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults (2022) (120)
- High frequencies of circulating IFN‐γ‐secreting CD8 cytotoxic T cells specific for a novel MHC class I‐restricted Mycobacterium tuberculosis epitope in M. tuberculosis‐infected subjects without disease (2000) (120)
- Prime-boost immunisation strategies for tuberculosis. (2005) (119)
- Antibodies and tuberculosis (2016) (115)
- Nitric Oxide Modulates Metabolic Remodeling in Inflammatory Macrophages through TCA Cycle Regulation and Itaconate Accumulation (2019) (113)
- Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial (2021) (113)
- Tuberculosis vaccines in clinical trials (2011) (112)
- Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial (2015) (111)
- Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. (2017) (108)
- Boosting with Poxviruses Enhances Mycobacterium bovis BCG Efficacy against Tuberculosis in Guinea Pigs (2005) (108)
- Co-infection with HIV and TB: double trouble (2005) (107)
- A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data☆ (2014) (106)
- Immunological Outcomes of New Tuberculosis Vaccine Trials: WHO Panel Recommendations (2008) (100)
- Ratio of Monocytes to Lymphocytes in Peripheral Blood Identifies Adults at Risk of Incident Tuberculosis Among HIV-Infected Adults Initiating Antiretroviral Therapy (2013) (98)
- Association of Human Antibodies to Arabinomannan With Enhanced Mycobacterial Opsonophagocytosis and Intracellular Growth Reduction (2016) (94)
- Evaluation of the Safety and Immunogenicity of a Candidate Tuberculosis Vaccine, MVA85A, Delivered by Aerosol to the Lungs of Macaques (2013) (88)
- Delaying Bacillus Calmette-Guérin Vaccination from Birth to 4 1/2 Months of Age Reduces Postvaccination Th1 and IL-17 Responses but Leads to Comparable Mycobacterial Responses at 9 Months of Age (2010) (85)
- Progress and challenges in TB vaccine development (2018) (84)
- A Human Challenge Model for Mycobacterium tuberculosis Using Mycobacterium bovis Bacille Calmette-Guérin (2012) (83)
- Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A (2015) (83)
- Prime-boost immunization strategies for infectious diseases. (2002) (81)
- The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses (2014) (79)
- Online Social Endorsement and Covid-19 Vaccine Hesitancy in the United Kingdom (2021) (79)
- The Humoral Immune Response to BCG Vaccination (2019) (79)
- Inhibition of Mycobacterial Growth In Vitro following Primary but Not Secondary Vaccination with Mycobacterium bovis BCG (2013) (78)
- Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. (2011) (78)
- The association between the ratio of monocytes:lymphocytes at age 3 months and risk of tuberculosis (TB) in the first two years of life (2014) (77)
- Human CD68 promoter GFP transgenic mice allow analysis of monocyte to macrophage differentiation in vivo. (2014) (77)
- Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A (2009) (76)
- Vaccination against tuberculosis: how can we better BCG? (2013) (76)
- Impaired IFN-γ-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART (2006) (72)
- Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials (2007) (71)
- A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. (2012) (70)
- Evaluation of a Human BCG Challenge Model to Assess Antimycobacterial Immunity Induced by BCG and a Candidate Tuberculosis Vaccine, MVA85A, Alone and in Combination (2013) (66)
- Immunogenicity and Protective Efficacy of Prime-Boost Regimens with Recombinant ΔureC hly+Mycobacterium bovis BCG and Modified Vaccinia Virus Ankara Expressing M. tuberculosis Antigen 85A against Murine Tuberculosis (2008) (65)
- A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis (2016) (64)
- Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. (2006) (63)
- Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines. (2014) (61)
- Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis (2014) (60)
- Injection fears and COVID-19 vaccine hesitancy (2021) (58)
- Identification of Major Factors Influencing ELISpot-Based Monitoring of Cellular Responses to Antigens from Mycobacterium tuberculosis (2009) (55)
- Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa (2008) (54)
- Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants (2011) (54)
- Vaccine Platform for Prevention of Tuberculosis and Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1 through Breastfeeding (2007) (54)
- CD8+ T cell‐mediated suppression of intracellular Mycobacterium tuberculosis growth in activated human macrophages (2003) (53)
- In vitro mycobacterial growth inhibition assays: A tool for the assessment of protective immunity and evaluation of tuberculosis vaccine efficacy. (2016) (52)
- Why don’t we have an effective tuberculosis vaccine yet? (2016) (52)
- Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery☆ (2013) (52)
- A comparison of IFNgamma detection methods used in tuberculosis vaccine trials. (2008) (51)
- Aerosol immunisation for TB: matching route of vaccination to route of infection (2015) (51)
- Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining (2010) (50)
- Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis Vaccines (2015) (50)
- Enhanced protection conferred by mucosal BCG vaccination associates with presence of antigen-specific lung tissue-resident PD-1+ KLRG1− CD4+ T cells (2018) (50)
- Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial (2019) (49)
- Investigating the Induction of Vaccine-Induced Th17 and Regulatory T Cells in Healthy, Mycobacterium bovis BCG-Immunized Adults Vaccinated with a New Tuberculosis Vaccine, MVA85A (2010) (49)
- BCG: myths, realities, and the need for alternative vaccine strategies. (2012) (48)
- A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults (2011) (44)
- TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development (2017) (43)
- The Tuberculin Skin Test (TST) Is Affected by Recent BCG Vaccination but Not by Exposure to Non-Tuberculosis Mycobacteria (NTM) during Early Life (2010) (43)
- Mycobacterial growth inhibition in murine splenocytes as a surrogate for protection against Mycobacterium tuberculosis (M. tb). (2013) (41)
- A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults (2019) (41)
- Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG (2013) (40)
- Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults (2012) (40)
- Identification and Evaluation of Novel Protective Antigens for the Development of a Candidate Tuberculosis Subunit Vaccine (2018) (40)
- Factors influencing the higher incidence of tuberculosis among migrants and ethnic minorities in the UK. (2018) (40)
- Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge (2022) (40)
- Vaccine strategies against tuberculosis. (2009) (37)
- Preclinical Development of an In Vivo BCG Challenge Model for Testing Candidate TB Vaccine Efficacy (2011) (37)
- Th1/Th17 Cell Induction and Corresponding Reduction in ATP Consumption following Vaccination with the Novel Mycobacterium tuberculosis Vaccine MVA85A (2011) (37)
- The association between the ratio of monocytes: lymphocytes and risk of tuberculosis among HIV-infected postpartum women. (2014) (36)
- A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults (2015) (35)
- Distinct Transcriptional and Anti-Mycobacterial Profiles of Peripheral Blood Monocytes Dependent on the Ratio of Monocytes: Lymphocytes. (2015) (35)
- A Multi-Antigenic Adenoviral-Vectored Vaccine Improves BCG-Induced Protection of Goats against Pulmonary Tuberculosis Infection and Prevents Disease Progression (2013) (35)
- Tuberculosis vaccines: progress and challenges. (2011) (35)
- Identification of antigens presented by MHC for vaccines against tuberculosis (2020) (34)
- Development of a BCG challenge model for the testing of vaccine candidates against tuberculosis in cattle (2014) (34)
- Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection (2018) (33)
- A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults (2016) (33)
- Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges (2019) (32)
- WHO preferred product characteristics for new vaccines against tuberculosis. (2018) (31)
- The Cross-Species Mycobacterial Growth Inhibition Assay (MGIA) Project, 2010–2014 (2017) (31)
- Developing an improved vaccine against tuberculosis (2004) (30)
- Cytomegalovirus infection is a risk factor for TB disease in Infants (2017) (30)
- The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays (2017) (29)
- Translational Mini‐Review Series on Vaccines: Development and evaluation of improved vaccines against tuberculosis (2007) (29)
- Enhancing the Biological Relevance of Machine Learning Classifiers for Reverse Vaccinology (2017) (29)
- Cytomegalovirus infection is a risk factor for tuberculosis disease in infants (2019) (28)
- Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-β1 (2008) (27)
- Dual Neonate Vaccine Platform against HIV-1 and M. tuberculosis (2011) (27)
- Distinct Transcriptional and Anti-Mycobacterial Profiles of Peripheral Blood Monocytes Dependent on the Ratio of Monocytes: Lymphocytes (2015) (27)
- Gene Expression and Cytokine Profile Correlate With Mycobacterial Growth in a Human BCG Challenge Model (2014) (27)
- Identification of antigens presented by MHC for vaccines against tuberculosis (2020) (26)
- Susceptibility to tuberculosis – the importance of the pathogen as well as the host (2003) (25)
- Towards new TB vaccines (2020) (25)
- The Role of Clinical Symptoms in the Diagnosis of Intrathoracic Tuberculosis in Young Children (2015) (25)
- TB vaccine development: where are we and why is it so difficult? (2014) (25)
- Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A (2013) (25)
- Clinical Testing of Tuberculosis Vaccine Candidates. (2016) (25)
- The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial (2017) (25)
- Induction and maintenance of a phenotypically heterogeneous lung tissue-resident CD4+ T cell population following BCG immunisation (2018) (24)
- Tuberculin Skin Testing and Treatment Modulates Interferon-Gamma Release Assay Results for Latent Tuberculosis in Migrants (2014) (24)
- Identification of Antigens Specific to Non-Tuberculous Mycobacteria: The Mce Family of Proteins as a Target of T Cell Immune Responses (2011) (24)
- Insights and challenges in tuberculosis vaccine development. (2019) (24)
- Evaluation of Xpert® MTB/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial (2015) (23)
- Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial (2021) (23)
- Disseminated Penicillium marneffei infection presenting as a right upper lobe mass in an HIV positive patient (1998) (22)
- Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection (2012) (22)
- Replacing, reducing and refining the use of animals in tuberculosis vaccine research. (2016) (22)
- Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A (2014) (21)
- A review of clinical models for the evaluation of human TB vaccines (2016) (21)
- Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines (2018) (21)
- A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants. (2012) (21)
- Regulation of mycobacterial infection by macrophage Gch1 and tetrahydrobiopterin (2018) (21)
- Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response (2014) (21)
- Cholera Toxin Enhances Vaccine-Induced Protection against Mycobacterium Tuberculosis Challenge in Mice (2013) (20)
- Editorial Commentary: Understanding BCG Is the Key to Improving It (2013) (20)
- Human Immunodeficiency Virus Infection Impairs Th1 and Th17 Mycobacterium tuberculosis–Specific T-Cell Responses (2018) (19)
- Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection (2020) (19)
- SARS-CoV-2 Human Challenge Studies - Establishing the Model during an Evolving Pandemic. (2021) (18)
- Optimisation, harmonisation and standardisation of the direct mycobacterial growth inhibition assay using cryopreserved human peripheral blood mononuclear cells (2019) (18)
- TB vaccines in clinical development. (2016) (18)
- Human Hookworm Infection Enhances Mycobacterial Growth Inhibition and Associates With Reduced Risk of Tuberculosis Infection (2018) (17)
- Optimization of a Human Bacille Calmette-Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity (2015) (17)
- Heterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell function (2013) (16)
- The next 10 years for tuberculosis vaccines: do we have the right plans in place? (2013) (16)
- Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults (2012) (16)
- Effect of dose and route of immunisation on the immune response induced in cattle by heterologous Bacille Calmette-Guerin priming and recombinant adenoviral vector boosting. (2014) (16)
- Current approaches toward identifying a correlate of immune protection from tuberculosis (2018) (15)
- Hepcidin deficiency and iron deficiency do not alter tuberculosis susceptibility in a murine M.tb infection model (2018) (14)
- Local Pulmonary Immunological Biomarkers in Tuberculosis (2021) (14)
- Ex vivo mycobacterial growth inhibition assay (MGIA) for tuberculosis vaccine testing - a protocol for mouse splenocytes (2015) (14)
- Elevated IgG Responses in Infants Are Associated With Reduced Prevalence of Mycobacterium tuberculosis Infection (2018) (13)
- Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects (2013) (12)
- Third human challenge trial conference, Oxford, United Kingdom, February 6-7, 2020, a meeting report. (2020) (12)
- The effect of tuberculin skin test and BCG vaccination on the expansion of PPD-specific IFN-gamma producing cells ex vivo. (2007) (11)
- Tuberculosis vaccines: current status and future prospects (2006) (11)
- Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A (2014) (10)
- Controlled Human Infection Models: Is it Really Feasible to Give People Tuberculosis? (2020) (10)
- Designing an adaptive phase II/III trial to evaluate efficacy, safety and immune correlates of new TB vaccines in young adults and adolescents. (2013) (10)
- Cross-laboratory evaluation of multiplex bead assays including independent common reference standards for immunological monitoring of observational and interventional human studies (2018) (10)
- Erratum: Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans (2004) (10)
- New TB vaccine granted orphan drug status (2005) (9)
- Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children (2015) (9)
- Lessons from the pandemic on the value of research infrastructure (2021) (9)
- Viral Booster Vaccines Improve Mycobacterium bovis BCG-Induced Protection against Bovine Tuberculosis (2011) (9)
- Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial (2017) (9)
- A New Vaccine for Tuberculosis: The Challenges of Development and Deployment (2009) (9)
- Immunogenicity and Protective Efficacy of Prime-Boost Regimens with Recombinant ΔureC hly + Mycobacterium bovis BCG and Modified Vaccinia Virus Ankara Expressing M. tuberculosis Antigen 85A against Murine Tuberculosis (2011) (9)
- Individual-level factors associated with variation in mycobacterial-specific immune response: Gender and previous BCG vaccination status. (2016) (8)
- Tuberculosis vaccines in the era of Covid-19 – what is taking us so long? (2022) (8)
- Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination (2022) (8)
- Influence of Aerosol Delivered BCG Vaccination on Immunological and Disease Parameters Following SARS-CoV-2 Challenge in Rhesus Macaques (2022) (8)
- Distinct blood transcriptomic signature of treatment in latent tuberculosis infected individuals at risk of developing active disease. (2021) (8)
- Factors influencing the higher incidence of tuberculosis among migrants and ethnic minorities in the UK (2018) (7)
- Markers of achievement for assessing and monitoring gender equity in a UK National Institute for Health Research Biomedical Research Centre: A two-factor model (2020) (7)
- Assay optimisation and technology transfer for multi-site immuno-monitoring in vaccine trials (2017) (7)
- Evaluation of liquid culture for quantitation of Mycobacterium tuberculosis in murine models. (2007) (7)
- Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination (2017) (7)
- Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants (2016) (7)
- Using Data from Macaques To Predict Gamma Interferon Responses after Mycobacterium bovis BCG Vaccination in Humans: a Proof-of-Concept Study of Immunostimulation/Immunodynamic Modeling Methods (2017) (7)
- Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review (2016) (6)
- A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development (2017) (6)
- Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines (2013) (6)
- Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model (2021) (6)
- Tuberculosis vaccine promises sterilizing immunity (2011) (6)
- Rapid research response to the COVID-19 pandemic: perspectives from a National Institute for Health Biomedical Research Centre (2022) (5)
- A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates (2021) (5)
- Developing vaccines to prevent sustained infection with Mycobacterium tuberculosis: Conference proceedings: National Institute of Allergy and Infectious Diseases, Rockville, Maryland USA, November 7, 2014. (2015) (5)
- A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity (2012) (5)
- Equity for excellence in academic institutions: a manifesto for change (2021) (5)
- Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): a phase 2 randomised adaptive trial (2021) (5)
- Tuberculosis vaccines: present and future (2008) (5)
- Comparison of haematology and biochemistry parameters in healthy South African infants with laboratory reference intervals (2017) (5)
- Efficacy of follow-up and contact tracing of women who test positive for genital tract chlamydia trachomatis prior to pregnancy termination (2004) (5)
- Differential Cytokine Levels in Adults Induced by a Novel Candidate TB Boost Vaccine, MVA85A-According to Previous BCG Vaccination Status (2012) (4)
- Heterologous prime-boost with Ad35/AERAS-402 and MVA85A elicits potent CD8+ T cell immune responses in a phase I clinical trial (VAC7P.969) (2014) (4)
- tuberculosis amongst patients initiating antiretroviral therapy (2013) (4)
- Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults (2021) (4)
- Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A (2018) (3)
- Investigating Immune Responses to Aerosol BCG Challenge in Healthy UK Adults (2019) (3)
- Induction of specific antibodies, IgG-secreting plasmablasts and memory B cells following BCG vaccination (2021) (3)
- Need for more TB vaccine field sites. (2009) (3)
- High dose aerosol challenge with Mycobacterium tuberculosis fails to overcome BCG vaccination-induced protection in cynomolgus macaques of Chinese origin: implications of natural resistance for TB vaccine evaluation. (2021) (2)
- A large National Institute for Health Research (NIHR) Biomedical Research Centre facilitates impactful cross-disciplinary and collaborative translational research publications and research collaboration networks: a bibliometric evaluation study (2021) (2)
- VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy (2018) (2)
- Incidental Diagnosis in Healthy Clinical Trial Subjects (2012) (2)
- Tuberculosis and the Tubercle Bacillus, Second Edition (2017) (2)
- Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin (BCG) for Infants of HIV Infected Mothers: A Phase 2 Randomized Controlled Trial. (2017) (2)
- Current transmission prevention methods: Vaccination (2014) (2)
- Evaluating the sensitivity of the bovine BCG challenge model using a prime boost Ad85A vaccine regimen. (2019) (2)
- Investigating the Induction of Vaccine-Induced Th17 and Regulatory T Cells in Healthy, Mycobacterium bovis BCG Immunized Adults Vaccinated with a New Tuberculosis Vaccine, MVA85A (2011) (2)
- TB Vaccine Development (2018) (2)
- Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study (2022) (1)
- Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants (2022) (1)
- The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells. (2021) (1)
- Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects (2013) (1)
- BCG and Other Vaccines (2020) (1)
- Helen McShane and colleagues reply to Deborah Cohen (2018) (1)
- Enhanced protection conferred by mucosal BCG vaccination associates with presence of antigen-specific lung tissue-resident PD-1+ KLRG1− CD4+ T cells (2018) (1)
- Vaccines for tuberculosis. (2013) (1)
- Global progress in tuberculosis vaccine development (2012) (1)
- High-dose Mycobacterium tuberculosis aerosol challenge cannot overcome BCG-induced protection in Chinese origin cynomolgus macaques; implications of natural resistance for vaccine evaluation (2021) (1)
- From AIDS to TB vaccines — A career in infectious diseases and translational vaccinology (2016) (1)
- Vaccine Platform for Prevention of Tuberculosis and Mother-to-Child Transmission of HIV-1 through Breastfeeding (2007) (1)
- “It seems impossible that it’s been made so quickly”: a qualitative investigation of concerns about the speed of COVID-19 vaccine development and how these may be overcome (2022) (1)
- Global progress in TB vaccine development (2013) (1)
- Ten minutes with Professor Helen McShane, Director, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust (2020) (1)
- Corrections (1991) (0)
- Tuberculosis vaccines in the era of Covid-19 (cid:1) what is taking us so long? (2022) (0)
- Corrections (1953) (0)
- SARS-CoV-2 Human Challenge Studies. Reply. (2021) (0)
- University of Birmingham Optimization of a human Bacille Calmette-Guérin challenge model (2016) (0)
- Challenges in Developing a Controlled Human Tuberculosis Challenge Model. (2022) (0)
- Department of Error (2013) (0)
- Correction: MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques (2011) (0)
- PRECLINICAL EVALUATION OF TB VACCINES (2014) (0)
- Safety and Immunogenicity of a Candidate Tuberculosis Vaccine ChAdOx1-85A Delivered by Aerosol Versus Intramuscular Route in Healthy Adults in a Phase 1, Double-Blind Randomized Controlled Trial (2022) (0)
- Chapter 32 – Vaccines (2014) (0)
- Correction: Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials (2011) (0)
- Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection (2018) (0)
- Practical considerations for a TB controlled human infection model (TB-CHIM); the case for TB-CHIM in Africa, a systematic review of the literature and report of 2 workshop discussions in UK and Malawi (2023) (0)
- Tuberculosis 2019 3 Insights and challenges in tuberculosis vaccine development (2019) (0)
- New TB vaccine granted orphan drug status. Author's reply (2005) (0)
- New tuberculosis vaccines can diminish as well as enhance BCG induced protection: Results from a murine model SO THORAX CT Winter Meeting of the British-Thoracic-Society/British-Lung-Foundation (BTS/BLF) (2006) (0)
- Immunity to mycobacterial infection (PP-061) (2010) (0)
- IMMUNOLOGICAL ASPECTS Non-tuberculous mycobacteria have diverse effects on BCG ef fi cacy against Mycobacterium tuberculosis (2014) (0)
- Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A (2011) (0)
- A survey to explore new markers of achievement to assess and monitor gender equity in an NIHR Biomedical Research Centre: A two-factor model (2020) (0)
- Evaluation of immunological mechanisms induced by Mycobacterium avium exposure and the effect upon pre-existing BCG immunity (2011) (0)
- The Evaluation of Prime-Boost Immunisation Strategies in a Murine Model of Tuberculosis (2001) (0)
- CD4 T cell response to MVA85A vaccination against Mycobacterium tuberculosis in healthy HIV-infected adults (2011) (0)
- One Hundred Years of BCG: The World’s Most Widely Used Vaccine (2021) (0)
- Author Correction: The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays (2019) (0)
- Regulation of mycobacterial infection by macrophage Gch1 and tetrahydrobiopterin (2018) (0)
- Author Correction: The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays (2019) (0)
- Publishing vaccine trial results – Does there have to be a delay? (2014) (0)
- MVA85A: characterising the innate immune responses after vaccination and the effect of TLR1 levels on the acquired antigen-specific immune response (2011) (0)
- Towards new TB vaccines (2020) (0)
- Vaccine Platform for Prevention of Mother-to-Child Transmission of HIV-1 through Breastfeeding (2008) (0)
- Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa1 (2012) (0)
- The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells (2021) (0)
- Overview of Heterologous Prime-Boost Immunization Strategies (2009) (0)
- Progress and challenges in TB vaccine development [version 1; peer review: 2 approved] (2021) (0)
- Tuberculosis vaccine trials – Authors' reply (2013) (0)
- Disease State and Effect of Treatment Individuals : Associations with Clinical-Infected Mycobacterium tuberculosis-Secreting CD 4 T Cells in γ IFN-Direct Ex Vivo Analysis of Antigen-Specific (2001) (0)
- Immunity to mycobacterial infection (WS-061) Chairpersons: Kiyoshi Takatsu, Masaji Okada (2010) (0)
- Letter from the Editor (2016) (0)
- Tuberculosis Vaccines (2021) (0)
- New vaccines – improving the BCG vaccine (2012) (0)
- Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA 85 A in West Africa (2017) (0)
- S40 Optimisation of a human BCG challenge model (2015) (0)
- Bacille Calmette–Guerin and Prospects for New Vaccines against Tuberculosis (2014) (0)
- by Aerosol to the Lungs of Macaques Tuberculosis Vaccine, MVA85A, Delivered Immunogenicity of a Candidate Evaluation of the Safety and (2013) (0)
- New vaccines in development and future direction (2011) (0)
- Using pox virus vector lacking replica to boost CD4 + T cell immune response to the antigen. (2001) (0)
- Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop (2022) (0)
- A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates (2021) (0)
- Session 7: Observing immunity: implications for rational vaccine design (2004) (0)
- Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa (2011) (0)
- OC 8259 THE VALIDATE NETWORK: EXPLOITING SYNERGIES BETWEEN COMPLEX INTRACELLULAR NEGLECTED PATHOGENS TO EXPEDITE VACCINE R&D FOR TUBERCULOSIS, LEISHMANIASIS, LEPROSY AND MELIOIDOSIS (2019) (0)
- Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults (2011) (0)
- Self-assessment questions: Global progress in tuberculosis vaccine development (2012) (0)
- Assessment of the reproducibility and inter-site transferability of the murine direct splenocyte mycobacterial growth inhibition assay (MGIA) (2021) (0)
- Clinical Evaluation of New Immunisation Strategies for Enhancing T Cell Responses against M. Tuberculosis (2003) (0)
- Recombinant Modified Vaccinia Virus Ankara Administration and Boosting with a Bacille Calmette-Guérin Vaccine Using Mucosal of Mycobacterium tuberculosis Efficacy Against Enhanced Immunogenicity and Protective (2003) (0)
- Disseminated Penicillium marne V ei infection presenting as a right upper lobe mass in an HIV positive patient (1998) (0)
- M36 Evaluating Aerosol Administration Of A Candidate Tb Vaccine Mva85a (2014) (0)
This paper list is powered by the following services:
Other Resources About Helen McShane
What Schools Are Affiliated With Helen McShane?
Helen McShane is affiliated with the following schools:
